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A Study of Elevated Interleukin-8
(CXCL8) and Detection of Leukocyte
Migration Inhibitory Activity in
Patients Allergic to Beta-Lactam
Antibiotics
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ABSTRACT
Background: The leukocyte migration test (LMT) is effective in identifying the causative drug in drug allergies.
Both leukocyte migration activating activity (LMAA) and leukocyte migration inhibitory activity (LMIA) are in-
volved in the development of drug allergies. However, no cytokines associated with LMIA have been identified
to date. Because CXCL8 played an important role in neutrophil infiltration and activation, we performed the
LMT and measured CXCL8 levels in patients with hypersensitivity to beta-lactam antibiotics (beta-lactams) and
antipyretic analgesics (APAs) and investigated the pathogenic mechanism of hypersensitivity to these drugs.
Methods: The LMT was performed according to an improved version of the agarose plate method and CXCL8
levels in the reacted solution that had been stored as described were measured using a solid-phase sandwich
enzyme-linked immunosorbent assay.
Results: Migration index (MI) values for the LMT were 77.7 ± 11.7 for patients with hypersensitivity to beta-
lactams and 83.6 ± 1.9 for those with hypersensitivity to APAs. The CXCL8 concentrations were significantly
higher in patients after beta-lactams administration (175.9 ± 71.2 ngmL) than those without beta-lactams ad-
ministration (48.3 ± 34.9 ngmL). The CXCL8 concentrations were significantly lower in patients after APAs ad-
ministration (41.7 ± 24.3 ngmL) than those without APAs administration (63.1 ± 30.2 ngmL).
Conclusions: Increased CXCL8 levels produced by beta-lactams administration were accompanied by LMIA.
CXCL8 may be involved in LMIA and play a role in beta-lactam allergies. In contrast, the LMIA detected in pa-
tients with allergies to APAs may be a cytokine or chemokine other than CXCL8.
KEY WORDS
hypersensitivity to antipyretic analgesics, hypersensitivity to beta-lactam antibiotics, interleukin-8, leukocyte mi-
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INTRODUCTION
Previously, we have reported that the leukocyte mi-
gration test (LMT) is more effective than the skin re-
action test, patch test, enzyme linked immunosorbent
assay (ELIZA), and drug-induced lymphocyte stimu-
lation test (DLST) in identifying drugs that cause
drug allergies.1-6 The 2 different activities detected by
the LMT―leukocyte migration activating activity
(LMAA) and leukocyte migration inhibitory activity
(LMIA)―are involved in the development of drug al-
lergies.1-3 In addition, cytokines such as interleukin
(IL)-1α, IL-2, and TNF-α are involved in initiating the
LMAA.7-9 However, to the best of our knowledge, no
cytokines correlated with LMIA have been identified
to date.
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Table　1　Patients with hypersensitivity to beta-lactam antibiotics
Case no. Age Sex Suspected drug
Latent 
period 
(days)
Allergic symptom Reacted MI† Control MI
† CRP Leukocyte ( ×103/mm3)
1 38 F CPDX-PR  1 Erythema 82 99 ± 9.0 ND ND
2 37 F CMZ  3 Erythema 82 99 ± 4.2 ND ND
3  4 M CEZ 11 Erythema 85 102 ± 4.7 ND ND
4 48 F CEZ  1 Erythema 82 102 ± 4.7 4.71 8.0
5 64 M CAZ  4 Fever (40.0°C) 75 103 ± 3.2 1.55 11.8
6 58 F FMOX  2 Erthema 69 102 ± 6.0 7.27 7.8
7 63 F FMOX  5 Erythema 79 102 ± 6.0 2.23 8.7
8 35 F FRPM  2 Erythema 85 103 ± 4.2 ND ND
9 28 M LMOX  6 Hepatopathy
 (ALP↑, GOT↑, GPT↑, 
LDH↑, γGTP↑)
85 96 ± 7.2 ND ND
10 58 F FMOX  6 Hepatopathy 
(ALP↑, GOT↑, GPT↑, 
LDH↑, γGTP↑)
85 102 ± 6.0 6.22 8.4
11 41 F CCL  1 Erythema, Fever (40.1°C) 46 100 ± 5.6 6.69 7.1
†MI, migration index; CRP, C-reactive protein; M, male; F, female; ND, not done; CPDX-PR, cefpodoxime proxetil; CMZ, cefmetazole; 
CEZ, cefazolin; CAZ, ceftazidime; FMOX, fl omoxef; FRPM, faropenem; LMOX, latamoxef; CCL, cefaclor.
Both beta-lactam antibiotics (beta-lactams) and an-
tipyretic analgesics (APAs) frequently cause drug
allergies.6,10,11 Chemokines have been reported to
participate in allergic diseases.12-14 Because IL-8
(CXCL8) played an important role in neutrophil infil-
tration and activation.15,16 Most leukocytes acting as
migration cells in the LMT are neutrophils.
In this study, we performed the LMT and meas-
ured CXCL8 levels in patients with hypersensitivity to
beta-lactams and in patients with hypersensitivity to
APAs to investigate the pathogenic mechanisms of
hypersensitivity to these classes of drugs.
METHODS
SUBJECTS
Subjects included patients who had been treated with
beta-lactams or APAs and who exhibited LMIA as de-
tected by LMT. These patients displayed hypersensi-
tivity following drug use, were found to improve
when use of the drug was discontinued, and were ex-
tremely unlikely to have an underlying condition and
a viral eruption; these patients were diagnosed with a
drug allergy by their primary physician.
Characteristics of the 11 patients (3 men and 8
women; age range, 4-64 years; average age, 43.1
years) with hypersensitivity to beta-lactams are
shown in Table 1. The hypersensitivity symptoms in-
cluded 8 cases of erythema, 2 cases of hepatopathy,
and 2 cases of fever. One patient exhibited both
erythema and fever. Each patient developed hyper-
sensitivity symptoms more than 1 h after the previous
administration of the drug. None of the skin symp-
toms were considered to be severe. Case No. 8 re-
ceived steroid treatment. C-reactive protein (CRP)
levels and neutrophil counts in the serum were meas-
ured in 6 patients and both values were high in all pa-
tients.
Drugs identified as allergens included the follow-
ing 8 types of beta-lactams: cefpodoxime proxetil
(CPDX-PR), cefaclor (CCL), faropenem (FRPM), ce-
fazolin (CEZ), cefmetazole (CMZ), ceftazidime
(CAZ), latamoxef (LMOX) and flomoxef (FMOX).
Characteristics of the 11 patients (4 men and 7
women; age range, 8-76 years; average age, 45.8
years) with hypersensitivity to APAs are shown in Ta-
ble 2. Hypersensitivity symptoms included 8 cases of
erythema, 3 cases of hepatopathy, and 1 case of urti-
caria. One patient had both erythema and hepatopa-
thy. Of the 11 patients, 10 patients developed hyper-
sensitivity symptoms after more than 1 h after drug
treatment and 1 patient (Case No. 22) developed
symptoms 30 min after drug treatment. None of the
skin symptoms were considered to be severe. Both
CRP levels and neutrophil counts in the serum were
measured in 6 patients and both values were high in
3 of the 6 patients.
Allergens included 7 types of APAs: acetamino-
phen, aspirin, mefenamic acid, diclofenac, alminopro-
fen, ketoprofen and ibuprofen.
We measured CXCL8 levels in 5 healthy volunteers
as controls (all men; average age, 36.2 years) without
any history of allergic diseases. This group was
treated with 2 types of beta-lactams (CPDX-PR and
CCL) and 2 types of APAs (acetaminophen and di-
clofenac).
Our study conformed to the guidelines described
in the Helsinki Declaration and was approved by the
appropriate judging committee of the Clinical Exami-
nation Department of Suibarago Hospital. Informed
consent was obtained from all subjects.
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Table　2　Patients with hypersensitivity to antipyretic analgesics
Case no. Age Sex Suspected drug
Latent 
period 
(days)
Allergic symptom Reacted MI† Control MI
† CRP Leukocyte (×103/mm3)
12 54 M Acetoaminophen 1 Erythema 80 99 ± 9.9 ND ND
13 30 F Acetoaminophen 2 Erythema 83 99 ± 9.9  6.69  7.1
14 56 F Mefenamic Acid 20 Hepatopathy
 (ALP↑, GOT↑, GPT↑, 
LDH↑, γGTP↑)
85 97 ± 7.5  0.10  5.8
15 29 F Diclofenac 7 Erythema 84 99 ± 7.7  2.65  9.0
16 68 M Aspirin 60 Erythema 85 98 ± 7.9 ND ND
17 8 F Diclofenac 3 Eythema 82 99 ± 7.7  0.20  3.34
18 70 M Alminoprofen 9 Erythema 81 97 ± 6.8 ND ND
19 76 F Diclofenac 1 Erythema 85 99 ± 7.7 ND ND
20 53 M Ketoprofen 15 Hepatopathy 
(GOT↑, GPT↑)
85 99 ± 7.6  0.06  4.8
21 17 F Diclofenac 3 Erythema, Hepatopathy 
(ALP↑, GOT↑, GPT↑, 
LDH↑, γGTP↑)
85 99 ± 7.7 11.87 11.0
22 43 F Ibuprofen 0.02 Urticaria 85 96 ± 3.5 ND ND
†MI, migration index; CRP, C-reactive protein; M, male; F, female; ND, not done.
ANTIGEN PREPARATION
The original powder of each tested drug was dis-
solved and diluted in Hanks’ balanced salt solution
(HBSS) (Gibco, Grand Island, NY, USA). We mixed
100 μL of this drug solution with 100 μL of the pa-
tient’s serum (as the antigen solution) in a 5-mL tube.
Water-insoluble drugs were dissolved in dimethyl sul-
foxide (DMSO) and diluted with HBSS. In addition,
100 μL HBSS mixed with 100 μL of the patient’s se-
rum without the drugs was used as a control.
The antigen concentrations of beta-lactams were
used to achieve about the maximum blood concentra-
tion of each drug in a single dose (CPDX-PR, 2 μg
mL; CCL, 10 μgmL; FRPM, 10 μgmL; CEZ, 100 μg
mL; CMZ, 100 μgmL; CAZ, 100 μgmL; LMOX, 100
μgmL; and FMOX, 100 μgmL).
However, APAs were prepared at approximately
half the level of a single dose (acetaminophen, 2.5
μgmL; aspirin, 5 μgmL; ibuprofen, 7.5 μgmL; me-
fenamic acid, 1.25 μgmL; diclofenac, 0.25 μgmL;
alminoprofen, 10 μgmL; and ketoprofen, 1 μgmL)
because they have little influence on leukocyte migra-
tion. Antigen preparation of drugs was performed im-
mediately before the reaction of antigen solution and
mononuclear cells (MCs).
REACTION OF ANTIGEN SOLUTION AND
MONONUCLEAR CELLS (MCs)
The reaction of the antigen solution and MCs was
carried out between 7 days and 3 months after the pa-
tient stopped administering the suspected drug. First,
heparinized blood was obtained from patient’ periph-
eral veins. MCs were obtained from the intermediate
centrifugation layer using Ficoll-Paque liquid (Phar-
macia Biotech, Uppsala, Sweden). After the cells
were washed 3 times with HBSS, they were prepared
to a cell count of 1.25 × 106 cellsmL in TC-199 cul-
ture medium (Gibco, Grand Island, NY, USA) con-
taining 10% inactivated horse serum suspended in 10
mM Hepes buffer. We added 800 μL of the MCs sus-
pension to 200 μL of the antigen solution or control
solution and this mixture was incubated in 5% CO2 in-
cubator at 37℃ for 72 h. These samples were centri-
fuged and the supernatant stored at −20℃. This solu-
tion was designated as the “reacted solution.”
LMT
The migration test was performed using an improved
version of the agarose plate method described by
Clausen.1-3,17 Briefly, leukocyte-rich plasma was ob-
tained from donors and separated from the
heparinized peripheral blood of healthy donors after
standing at 37℃ for 45 min in 14 of the volume con-
taining physiological saline supplemented with 5%
dextran. Polymorphonuclear leukocytes (PMNLs)
were obtained from the plasma sediments by centrifu-
gation using Ficoll-Paque liquid and erythrocytes
mixed in the PMNLs were lysed by osmotic shock.
The PMNLs were washed 3 times with physiological
saline and adjusted to a density of 2.5 × 108 cellsmL
in the reacted solution, which had been stored as de-
scribed. Samples of these suspensions (7 μL) were
placed in each well (Φ = 3 mm) of an agarose plate
prepared from the culture medium containing 1% aga-
rose. After incubating in a 5% CO2 incubator at 37℃
for 12-24 hours, the migration area of the PMNLs was
measured with an immunoviewer. For each test, the
extent of migration in 6 wells was examined.
Testing criteria were as follows: The migration in-
Abe M et al.
500 Allergology International Vol 60, No4, 2011 www.jsaweb.jp
Table　3　Migration indices of the leukocytes of suspected 
drugs and dimethyl sulfoxide
Tested agent Concentration (μg/mL)
Migration idex 
(M ± 2SD)
CPDX-PR   2 99 ± 9.0
CCL  10 100 ± 5.6
FRPM  10 103 ± 4.2
CEZ 100 102 ± 4.7
CMZ 100 99 ± 4.2
CAZ 100 103 ± 3.2
LMOX 100 96 ± 7.2
FMOX 100 102 ± 6.0
Acetoaminophen     2.5 99 ± 9.9
Aspirin   5 98 ± 7.9
Ibuprofen     7.5 96 ± 3.5
Mefenamic Acid      1.25 97 ± 7.5
Diclofenac      0.25 99 ± 7.7
Alminoprofen  10 97 ± 6.8
Ketoprofen   1 99 ± 7.6
Dimethyl sulfoxide   1 99 ± 5.5
CPDX-PR, cefpodoxime proxetil; CCL, cefaclor; FRPM, farope-
nem; CEZ, cefazolin; CMZ, cefmetazole; CAZ, ceftazidime; LMOX, 
latamoxef; FMOX, fl omoxef.
dex (MI) was calculated from the migration area us-
ing the formula: MI = (migration area of leukocytes in
supernatant from the MCs cultured with drugmigra-
tion area of leukocytes in supernatant from MCs cul-
tured without drug) × 100. If the MI value of the sub-
ject was below 85 and significantly lower than the MI
of the healthy volunteers according to a t-test, it was
considered to indicate the presence of LMIA.1-3,17
As controls, we performed migration tests for sus-
pected drugs and DMSO alone to investigate whether
these agents directly influence the migration of
PMNLs. Agents tested were applied at concentrations
used in patients with hypersensitivity to drugs. MI
was calculated as the mean ± 2SD units from the mi-
gration area using the following formula: MI = (mi-
gration area of leukocytes with drugmigration area
of leukocytes without drug) × 100.
CXCL8 ASSAY
CXCL8 in the reacted solution that had been stored
as described was measured by using a solid-phase
sandwich enzyme-linked immunosorbent assay
(ELISA) kit (Human interleukin-8 ELISA Kit, BIO-
SOURCE, CA, USA). The control solution conditions
were identical to those used in the LMT. After a 50
μL sample or standard solution was placed in a 96-
well microplate, 50 μL of biotinylated anti-IL-8 solu-
tion was added to each well and the mixture was incu-
bated at room temperature for 1.5 h. The reacted liq-
uid was then aspirated thoroughly and the well was
washed 4 times with Wash Buffer in the kit. A 100 μL
volume of streptavidine-HRP Working Solution (ac-
cessories in the kit) was added to each well and the
mixture was incubated at room temperature for 30
min. The liquid was then thoroughly aspirated and
the wells were washed 4 times with Wash Buffer.
Next, 100 μL of Stabilized Chromogen was added to
each well and this mixture was incubated in the dark
at room temperature for 30 min. Subsequently, 100
μL of Stop Solution was added to each well and the
microplate was stirred using a plate mixer. Optical
density (OD) was measured at 450 nm with an ELISA
reader (Titertek Multiskan MCC340, Flow Laborato-
ries Inc., Helsinki, Finland). CXCL8 concentration
was calculated by constructing a calibration curve
from the standard solution OD.
RESULTS
LMT
MI values of patients with hypersensitivity to beta-
lactams according to the LMT are shown in Table 1.
With a mean value of 77.7 ± 11.7 (mean ± SE), these
values are significantly lower than MI values of the
healthy volunteers on the basis of a t-test. MI values
of patients with hypersensitivity to APAs according to
the LMT are shown in Table 2. On the basis of t-test,
the mean value (83.6 ± 1.9) is significantly lower than
the MI values of the healthy volunteers.
Migration indices of leukocytes of the suspected
drugs and DMSO are shown Table 3. All suspected
drugs and DSMO failed to influence the leukocyte
migration at the concentration used in patients with
hypersensitivity to drugs.
CXCL8
Figure 1 shows CXCL8 concentrations measured
with or without the suspected drug in patients with
hypersensitivity to beta-lactams and in healthy volun-
teers. In healthy volunteers, the CXCL8 concentra-
tion was 65.6 ± 13.7 ngmL without the drug and
64.6 ± 18.6 ngmL with the drug. There was no sig-
nificant difference between the 2 groups. On the
other hand, the CXCL8 concentration was 48.3 ± 34.9
ngmL without the drug in patients with hypersensi-
tivity to beta-lactams and significantly higher at a
value of 175.9 ± 71.2 ngmL with the drug (p < 0.005,
paired t-test).
Figure 2 shows CXCL8 concentrations with or
without the drug in patients with hypersensitivity to
APAs and in healthy volunteers. In the healthy volun-
teers, the CXCL8 concentration is 74.6 ± 9.9 ngmL
without the drug and 74.0 ± 15.5 ngmL with the
drug. There is no significant difference between the 2
groups. In contrast, the CXCL8 concentration was
63.1 ± 30.2 ngmL without the drug in patients with
hypersensitivity to APAs and significantly lower at
41.7 ± 24.3 ngmL with the drug (p < 0.005, paired t-
test).
Role of Interleukin-8 in Drug Allergies
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Fig.　1　The concentration of CXCL8  with or without  drug in (a)  healthy volunteers and in (b) patients suspect-
ed of hypersensitivity to beta-lactam antibiotics.
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Fig.　2　The concentration of CXCL8 with or without drug in (a) healthy volunteers and in (b) patients suspected 
of hypersensitivity to antipyretic analgesics (b).
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EFFECT OF CXCL8 ON LEUKOCYTE MIGRA-
TION
The population of PMNLs (n = 50) used as migration
cells for the LMT was 91.0% ± 1.7% (88.6-95.4%) in
neutrophils, 4.3% ± 1.2% (2.3-7.2%) in monocytes and
4.7% ± 1.0% (2.6-6.4%) in lymphocytes. Figure 3 shows
the effect of CXCL8 on 7 different concentrations
(one concentration was measured by 12 specimens
each) with respect to the process of leukocyte migra-
tion on an agarose plate. CXCL8 inhibits the migra-
tion of leukocytes at concentrations greater than 25
ngmL. Therefore, the CXCL8 concentrations de-
tected in patients with hypersensitivity to beta-
lactams were within the range of concentrations at
Abe M et al.
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Fig.　3　The effect on CXCL8 in the leukocyte migration on agarose plate. 
*41.7 ± 24.3; the concentration of CXCL8 detecetd in patients with hypersensitivity to anti-
pyretic analgesics. 
**175.9 ± 71.2; the concentration of CXCL8 detected in patients with hypersensitivity to beta-
lactam antibiotics. 
***t-test.
70
80
90
100
110
120
5 10 25 50 100 250 500
MI (%)
ng/ml
175.9 ± 71.2**41.7 ± 24.3*
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p < 0.0005***
which CXCL8 inhibits migration of leukocytes.
DISCUSSION
The most common methods used to detect allergenic
drugs are the DLST and the patch test. However, the
positive rates of detection using these methods are
not as high as expected. The LMT is an effective
method of detecting allergenic drugs. In cases where
the DLST, patch test, and LMT were performed on
patients with suspected drug hypersensitivity, we re-
ported that the positive rate of LMT was higher and
more effective than positive rates determined by
DLST5 and patch test.6
In contrast to well-known IgE-mediated reactions
that exhibit immediate onset, many drug-induced hy-
persensitivity reactions appear delayed. It is thought
that these delayed hypersensitivity reactions (type
IV) may be further classified into T-cell reactions,
which release specific cytokines and chemokines and
preferentially activate and recruit monocytes (type
IVa), eosinophils (type IVb), or neutrophils (type
IVd).18 Moreover, cytotoxic functions by either CD4+
or CD8+ T-cells (type IVc) appear to participate in all
type IV reactions. CXCL8 is an important factor ex-
hibiting chemotaxis for target cells such as neutro-
phils15,16 and may be involved in drug-induced acute
generalized exanthematous pustulosis.19 In addition,
Th1Tc1 and Th17Tc17 may be involved in the ap-
pearance of a type IV allergic reaction.20 IL-17 in par-
ticular is thought to be heavily involved in a type IVd
reaction.21-23 Moreover, IL-17 induces the production
of CXCL8.24-27 Therefore, CXCL8 may be primarily in-
volved in the type IVd reaction.
Most subjects developed hypersensitivity symp-
toms more than one hour after drug administration.
Accordingly, most of these drug-induced hypersensi-
tivity reactions may be induced by the type IV reac-
tion which includes the participation of CXCL8. In the
case of Patient No. 22, hypersensitivity symptoms de-
veloped only 30 minutes after drug administration. It
is worth noting that the hypersensitivity reaction of
this case may have been induced by the immediate
IgE-mediated reaction involving low CXCL8 levels.
Because of this, CXCL8 production may not be recog-
nized in Patient No. 22.
CRP and neutrophil levels increased in most cases
of hypersensitivity to beta-lactams. This suggests that
CRP and neutrophils may participate in the type IVd
reaction. However, CRP and neutrophil levels in-
creased in only half of the cases of hypersensitivity to
APAs. This indicates that the anti-inflammatory action
of APAs may influence CRP and neutrophil levels.
There is no significant difference in hypersensitiv-
ity symptoms with respect to eruption and hepatopa-
thy at different CXCL8 production levels, suggesting
that hypersensitivity symptoms are not correlated
with CXCL8 production.
LMIA in the agarose plate method of LMT is
Role of Interleukin-8 in Drug Allergies
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thought to demonstrate chemotaxis. Since leukocytes
undergo chemokinesis, they migrate on an agarose
plate. However, if a sample and leukocytes are both
placed in the same well of an agarose plate, the leuko-
cytes may be attracted to the sample, effecting che-
motaxis by inhibiting migration.
With respect to the hypersensitivity symptoms of
eruption and hepatopathy, there was a significantly
greater extent of LMAA in hypersensitivity to beta-
lactams than LMIA and a greater extent of LMIA in
hypersensitivity to APAs than LMAA.6,10 The mecha-
nism of onset of hypersensitivity to beta-lactams and
APAs may be different.
In this study, CXCL8 production increased in pa-
tients allergic to beta-lactams and in whom LMIA was
detected. Furthermore, neutrophils accounted for
more than 90% of the leukocytes used in the LMT and
CXCL8 showed the effect of LMIA on agarose plates
at concentrations within a range detected in patients
with this allergy. These findings suggest that the
LMIA detected in the patients with this allergy may
be CXCL8. However, we cannot rule out other cytoki-
nes or chemokines showing LMIA and it is necessary
to investigate this point in the future. Accordingly,
CXCL8 may be highly involved in LMIA and play a
role in allergic reaction to beta-lactams. However,
LMIA may involve other cytokines or chemokines in
addition to CXCL8. We previously reported that IL-1,
IL-2, and TNF-α are involved in the production of
LMAA.7-9 In addition, it has been shown that both IL-
1 and TNF-α possess chemokinesis activity and IL-2
dose not.9 Both IL-1 and TNF-α are inflammatory cy-
tokines, while IL-2 is a cytokine involved in the regu-
lation of Th1-produced cell-mediated immunity. Con-
sequently, it may be possible to develop a chemical
assay using IL-1 (or IL-2 or TNF-α) and CXCL8 in pa-
tients with hypersensitivity to beta-lactams.
In contrast, CXCL8 production was not enhanced
in patients exhibiting allergic reactions to APAs and
in whom LMIA was detected. Incidentally, it is
thought that there are no influences of APAs and
DMSO in CXCL8 production because the agents did
not decrease leukocyte migration or the CXCL8 pro-
duction. Therefore, the LMIA detected in patients
with APA allergies may not be CXCL8, but some
other cytokine or chemokine not yet identified to be
involved in this process.
It has been reported that both CD8+ and CD4+ T-
cells are in involved in drug allergies.28 CD8+ T-cells
may include Tc1 and Tc2 cells based on their
cytokine production patterns in a manner similar to
CD4+ T-cells. CD8+ T-cells contribute to the develop-
ment of type IVa and type IVc reactions in T-cell or-
chestrated hypersensitivity.18 IL-1 is an important fac-
tor for the type IVd reaction mechanism and TNF-α
for the type IVa and IVc reaction mechanism. We
found that both IL-1 and TNF-α are involved in LMAA
and CXCL8 is involved in LMIA.9 Therefore, in the al-
lergic reaction to beta-lactams, IL-1 or TNF-α may be
involved in LMAA and CXCL8 in LMIA. Additionally,
CXCL5, CXCL6, and CXCL7 regulate PMNLs chemo-
taxis.29 These chemokines (with the exception of
CXCL8) may participate in APAs allergy onset. Fur-
thermore, immunocytes and cytokines involved in
drug allergies may differ depending upon the specific
causative drug (allergen).30,31 Therefore, it is essen-
tial to determine the cytokine responsible for allergic
reactions in patients with APA allergies, as well as to
review cytokine or chemokine participation in drug
allergies.
ACKNOWLEDGEMENTS
We performed this study during our stay at the De-
partment of Pharmacy, Suibarago Hospital and we
wish to thank the doctors and pharmacists of this
hospital who cooperated with our study.
CONFLICT OF INTEREST
No potential conflict of interest was disclosed.
REFERENCES
1. Uno K, Yamasaku F. Structural correlations with cross-
reactivity of β-lactam antibiotics in delayed type hypersen-
sitivity. Cross-allergenicity in hypersensitivity in hyper-
sensitivity to cephems with a tetrazolyl group in the C-3
side Chain. J Antimicrob Chemother 1989;24:251-64.
2. Uno K, Yamasaku F. Application of leucocyte migration
tests to detection of allergenic drugs in patients with hy-
persensitivity to β-lactam antibiotics. J Antimicrob Che-
mother 1989;24:241-50.
3. Uno K. [Studies on the pathogenic mechanism of β-
lactam hypersensitivity by the detection of leucocyte mi-
gration activating factor and leucocyte migration inhibi-
tory factor]. [Jpn J Allergol] 1990;39:1605-11(in Japa-
nese).
4. Nagakura N, Shimizu T, Yanagihara Y, Uno K. Leucocyte-
migration inhibition test and ELISA in patients with sus-
pected beta-lactam antibiotic allergy. Chemotherapy 1990;
38:910-7.
5. Saito M, Yagi M, Uno K, Takanaka K. Comparative study
of the usefulness of the drug-induced lymphocyte stimula-
tion test and the leukocyte migration test in drug aller-
gies. Biol Pharm Bull 2008;31:299-304.
6. Abe M, Uno K. [A study of clinical significance of leuco-
cyte migration test in drug eruption]. [Jpn J Allergol]
1998;47:1264-72(in Japanese).
7. Uno K. [Studies on the pathogenic mechanism of hyper-
sensitivity to antibacterial agents―Correlations of leuco-
cyte migration activating factor and leucocyte migration
inhibitory factor with interleukin-2 and interferon-γ―].
[Jpn J Allergol] 1993;42:656-64(in Japanese).
8. Sano N, Uno K. [Correlations of leucocyte migration acti-
vating factor with interleukin-1α, interleukin-1β and tu-
mor necrosis factor-α in drug allergy]. [Jpn J Allergol]
1998;47:1198-204(in Japanese).
9. Uno K. [Clinical analysis of drug allergies to detect causa-
tive drugs and determine other aspects of their patho-
genic mechanisms]. [Jpn J Pharm Health Care Sci] 2010;
36:613-34(in Japanese).
10. Abe M, Uno K. [A study on drug-induced hypersensitivity
Abe M et al.
504 Allergology International Vol 60, No4, 2011 www.jsaweb.jp
hepatic injury by leucocyte migration test]. [Jpn J Pharm
Health Care Sci] 2001;27:5-14(in Japanese).
11. Abe M, Kurihara T, Uno K. [Study on drug-induced hy-
persensitivity blood disorders using leukocyte migration
test]. [Jpn J Pharm Health Care Sci] 2005;31:32-40(in
Japanese).
12. Pizzichini MM, Pizzichini E, Efthimiadis A et al. Asthma
and natural colds. Inflammatory indices in induced spu-
tum: a feasibility study. Am J Respir Crit Care Med 1998;
158:1178-84.
13. Kuna P, Lazarovich M, Kaplan AP. Chemokines in sea-
sonal allergic rhinitis. J Allergy Clin Immunol 1996;97:
104-12.
14. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K.
Properties of the novel proinflammatory supergene “inter-
crine” cytokine family. Annu Rev Immunol 1991;9:617-48.
15. Baggiolini M, Dewald B, Moser B. Interleukin-8 and re-
lated chemotactic cytokines-CXC and CC chemokines.
Adv Immunol 1994;55:97-179.
16. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Mat-
sushima K. The neutrophil-activating protein (NAP-1) is
also chemotactic for T lymphocytes. Science 1989;243:
1464-6.
17. Clausen JE. Leukocyte migration agarose technique:
some technical details. Acta Allergol 1973;28:351-64.
18. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity re-
actions―new concepts. Clin Exp Allergy 2007;37:989-99.
19. Britschgi M, Steiner UC, Schmid S et al. T-cell involve-
ment in drug-induced acute generalized exanthematous
pustulosis. J Clin Invest 2001;107:1433-41.
20. Zhao Y, Balato A, Fishelevich R, Chapoval A, Mann DL,
Gaspari AA. Th17Tc17 infiltration and associated cy-
tokine gene expression in elicitation phase of allergic con-
tact dermatitis. Br J Dermatol 2009;161:1301-6.
21. Laan M, Cui ZH, Hoshino H et al. Neutrophi recruitment
by human IL-17 via C-X-C chemokine release in the air-
ways. J Immunol 1999;162:2347-52.
22. Pelletier M, Maggi L, Micheletti A et al. Evidence for a
cross-talk between human neutrophils and Th17 cells.
Blood 2010;115:335-43.
23. Roussel L, Houle F, Chan C et al. IL-17 promotes p38
MAPK-dependent endothelial activation enhancing neu-
trophil recruitment to sites of inflammation. J Immunol
2010;184:4531-7.
24. Britschgi M, Pichler WJ. Acute generalized exanthema-
tous pustulosis, a clue to neutrophil-mediated inflamma-
tory processes orchestrated by T cells. Curr Opin Allergy
Clin Immunol 2002;2:325-31.
25. Prause O, Laan M, Lötvall J, Lindén A. Pharmacological
modulation of interleukin-17-induced GCP-2-, GRO-alpha-
and interleukin-8 release in human bronchial epithelial
cells. Eur J Pharmacol 2003;462:193-8.
26. Henness S, van Thoor E, Ge Q, Armour CL, Hughes JM,
Ammit AJ. IL-17A acts via p38 MAPK to increase stability
of TNF-alpha-induced IL-8 mRNA in human ASM. Am J
Physiol Lung Cell Mol Physiol 2006;290:L1283-90.
27. Kabashima R, Sugita K, Sawada Y, Hino R, Nakamura M,
Tokura Y. Increased circulating Th17 frequencies and se-
rum IL-22 levels in patients with acute generalized exan-
thematous pustulosis. J Eur Acad Dermatol Venereol 2011;
25:485-8.
28. Hertl M, Geisel J, Boecker C, Merk HF. Selective genera-
tion of CD8+ T-cell clones from the peripheral blood of pa-
tients with cutaneous reactions to beta-lactam antibiotics.
Br J Dermatol 1993;128:619-26.
29. Ubagai T, Tansho S, Ito T, Ono Y. Influences of aflatoxin
B1 on reactive oxygen species generation and chemotaxis
of human polymorphonuclear leukocytes. Toxicol In Vitro
2008;22:1115-20.
30. Salgame P, Abrams JS, Clayberger C et al. Differing lym-
phokine profiles of functional subsets of human CD4 and
CD8 T cell clones. Science 1991;254:279-82.
31. Kemeny DM, Noble A, Holmes BJ, Diaz-Sanchez D. Im-
mune regulation: a new role for the CD8+ T cell. Immunol
Today 1994;15:107-10.
